Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.01.2021 | News item

Carboplatin: risk of posterior reversible encephalopathy syndrome

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

After performing a safety review, Health Canada has advised that use of carboplatin-containing products for ovarian cancer is associated with a risk of posterior reversible encephalopathy syndrome (PRES). Symptoms of PRES include headaches, seizures, vision problems, and nausea and vomiting. …
Metadaten
Titel
Carboplatin: risk of posterior reversible encephalopathy syndrome
Publikationsdatum
01.01.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-87822-3

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Crizotinib

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Clindamycin

Case report

Prednisone